Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

Listen to Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, as they discuss the clinical data that inform how they select later-line treatment for patients with mCRC.
Chiara Cremolini, MD, PhD
person default
Teresa Macarulla, MD
Released: December 17, 2021

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

  • Transitioning from second- to third-line therapy
  • Factors in selecting among available therapies
  • Key predictors of improved outcomes with regorafenib vs TAS-102

Information on this Educational Activity


Chiara Cremolini, MD, PhD

Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy

Chiara Cremolini, MD, PhD, has disclosed that she has received funds for research support from Amgen, Bayer, and Merck and consulting fees from Bayer, Merck, MSD, Nordic Pharma, Pierre Fabre, and Roche.
Teresa Macarulla, MD

Medical Oncologist
Vall d'Hebron Institute of Oncology
Barcelona, Spain

Teresa Macarulla, MD, has disclosed that she has received consulting fees from Ability, Advance Medical HCMS, AstraZeneca, Baxter, Celgene, Eisai, Genzyme, Incyte, Ispen, Lilly, Marketing Farmacéutico & Investigación Clínica SL, Merck Sharp and Dohme, QED, Roche, Sanofi, Servier, and Zymeworks.

Program Medium

This program has been made available online.


Supported by an educational grant from
Bayer HealthCare Pharmaceuticals Inc.

Related Content

Downloadable slideset with highlights from key gastrointestinal cancers as presented at 2022 ESMO World Congress on Gastrointestinal Cancer, from Clinical Care Options (CCO)

Released: August 16, 2022

Expert commentary on potential clinical implications of findings from the MOUNTAINEER trial with tucatinib and trastuzumab in HER2 positive metastatic colorectal cancer, from Clinical Care Options (CCO)

John Strickler, MD Released: August 10, 2022

Nina Beri, MD reviews ongoing clinical trials in targeted therapies for patients with cholangiocarcinoma presented at ASCO 2022, from Clinical Care Options (CCO)

person default Nina Beri, MD Released: August 3, 2022

Downloadable slideset on therapies for previously treated advanced HER2-negative gastric/GEJ cancers, from Clinical Care Options (CCO)

Samuel Klempner, MD Released: July 21, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings